Search

Your search keyword '"G. Papageorgiou"' showing total 333 results

Search Constraints

Start Over You searched for: Author "G. Papageorgiou" Remove constraint Author: "G. Papageorgiou" Topic business Remove constraint Topic: business
333 results on '"G. Papageorgiou"'

Search Results

1. Effect of Apolipoprotein E4 on the Driving Behavior of Patients with Amnestic Mild Cognitive Impairment or Mild Alzheimer’s Disease Dementia

2. PALMARIS LONGUS MUSCLE CONTRIBUTION TO MAXIMUM TORQUE AND STEADINESS IN HIGHLY SKILLED GRIP AND NON-GRIP SPORT POPULATIONS

3. APOE Genotype and Alzheimer’s Disease: The Influence of Lifestyle and Environmental Factors

4. Eating Disorders in Frontotemporal Dementia and Alzheimer’s Disease: Evaluation of Brain Perfusion Correlates Using 99mTc-HMPAO SPECT with Brodmann Areas Analysis

5. Hierarchical Approach to Integrated Planning of Industrial Gas Supply Chains

6. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece

7. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

8. Self-powered ultrasensitive and highly stretchable temperature–strain sensing composite yarns

9. The impact of COVID‐19 pandemic on people with mild cognitive impairment/dementia and on their caregivers

10. Erdheim–Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report

11. The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes

12. Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study

13. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry

14. Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group

15. Best of Both Worlds: Synergistically Derived Material Properties via Additive Manufacturing of Nanocomposites (Adv. Funct. Mater. 46/2021)

16. Best of Both Worlds: Synergistically Derived Material Properties via Additive Manufacturing of Nanocomposites

17. Apathy: an underestimated feature in GBA and LRRK2 non-manifesting mutation carriers

18. The power of sample size through a multi-scanner approach in MR neuroimaging regression analysis: evidence from Alzheimer’s disease with and without depression

19. RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES

20. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

21. Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study)

22. Driving and Alzheimer's dementia or mild cognitive impairment: a systematic review of the existing guidelines emphasizing on the neurologist's role

24. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study

25. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis

26. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas

27. Author response for 'REAL‐LIFE EXPERIENCE WITH THE COMBINATION OF POLATUZUMAB VEDOTIN, RITUXIMAB AND BENDAMUSTINE IN AGGRESSIVE B‐CELL LYMPHOMAS'

28. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies

29. Evolving Causes of Rapidly Progressive Dementia: A 5-Year Comparative Study

30. A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease

31. Force Steadiness during Submaximal Isometric Plantar and Dorsiflexion in Resistance Training: Experienced vs Non-experienced Individuals

32. Chronic myelomonocytic leukemia - a review

33. Differences of apathy perfusion correlates between Alzheimer's disease and frontotemporal dementia. A 99mTc-HMPAO SPECT study with automated Brodmann areas analysis

34. Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems?

35. Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications

36. Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study

37. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group

38. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database

39. A Prospective Phase II Study on The Use Of Convalescent Plasma Monotherapy For The Treatment of Severe Covid-19 Disease: A Preliminary Report

40. Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study

41. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

42. Incidence and cost of bleeding events requiring hospitalization in patients with atrial fibrillation treated with acenocoumarol in Greece

43. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease

44. Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes

45. Tuning the Properties of Furandicarboxylic Acid-Based Polyesters with Copolymerization: A Review

46. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes

47. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study

48. Predictors of accidents in people with mild cognitive impairment, mild dementia due to Alzheimer's disease and healthy controls in simulated driving

50. Integrated shale gas supply chain design and water management under uncertainty

Catalog

Books, media, physical & digital resources